FlandersBio on Twitter

Follow us on Twitter

Archive for November 2014 - News

Archive for November 2014 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Zevende aflevering van Z Life Sciences over de activiteiten van TiGeniX, ingeleid door KBC Securities, gemist? Bekijk de reportage hier opnieuw!

27.11.2014

De life sciences sector zoekt oplossingen voor onze gezondheid, landbouw en voeding. De sector telt in Vlaanderen zo’n 250 ondernemingen en 75 000 medewerkers in beloftevolle start-ups, internationale bedrijven, gerenommeerde onderzoeksinstellingen en ondersteunende organisaties.Z life sciences kijkt achter de schermen van deze innovatieve sector in volle expansie. Elke donderdag op Kanaal Z. read more

CARDIO3 BIOSCIENCES ANNOUNCES THE NOMINATION OF THREE CO-PRINCIPAL INVESTIGATORS FOR ITS CHART-2 PHASE III CLINICAL TRIAL OF C-CURE® FOR THE TREATMENT OF HEART FAILURE

26.11.2014

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today the appointment of its three Co-Principal Investigators for the CHART-2 study (Congestive Heart Failure cArdiopoietic Regenerative Therapy), authorized in the United States by the FDA in January, and anticipated to start by the end of 2014. read more

ABLYNX DEMONSTRATES BIOEQUIVALENCE BETWEEN LIQUID AND LYOPHILISED FORMULATIONS OF ITS ANTI-vWF NANOBODY, CAPLACIZUMAB

26.11.2014

Ablynx [Euronext Brussels: ABLX] today announced positive results from the Phase I trial to demonstrate bioequivalence between the liquid and lyophilised formulations of caplacizumab, Ablynx's anti-von Willebrand factor Nanobody developed for the treatment of acquired TTP. read more

Apitope Receives Orphan Designation in the European Union for ATX-F8-117 for the treatment of Haemophilia A

25.11.2014

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan medicinal product designation to ATX-F8-117 for the treatment of haemophilia A. read more

Promethera Biosciences raises €25.33 million ($31.4 million) in Series C financial round

25.11.2014

Promethera Biosciences, a Belgian biotechnology company developing Promethera® HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, today announces the completion of its Series C fundraising round. The company has raised €25.33 million ($31.4 million), including €20.33 million in capital. read more

GENTICEL WINS THE DELOITTE TECHNOLOGY FAST 50 “PRIX BIOTECH D'AVENIR 2014” AWARD

24.11.2014

GENTICEL (Euronext Paris & Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, has won the 1st “Prix Biotech d’Avenir 2014” (Most Promising Biotech Award) in Biotech - Life Sciences of SW France of the Deloitte Technology Fast 50 benchmark awards for technology companies. read more

Has a possible new lead been found in the fight against neurodegenerative diseases?

24.11.2014

Good communication between brain cells is vital for optimal (mental) health. Mutations in the TBC1D24 gene inhibit this process, thereby causing neurodegeneration and epilepsy. Fruit flies with a defect in Skywalker, the fruit fly variant of TBC1D24, are being used as a model for neurodegeneration. Researchers from VIB and KU Leuven have succeeded in completely suppressing neurodegeneration in such fruit flies, by partially inhibiting the breakdown of 'defective' proteins in brain cells. read more

Europa, Vlaanderen en Provincie Oost-Vlaanderen investeren samen 1,27 miljoen EURO in Gentse Bio Base Europe Pilot Plant

24.11.2014

Het programmasecretariaat EFRO Vlaanderen en Bio Base Europe Pilot Plant (BBEPP) ondertekenen vandaag een contract voor een investering van 1,27 miljoen EURO. Ongeveer een half miljoen EURO van dit bedrag komt uit het Europees Fonds voor Regionale Ontwikkeling (EFRO). Daarnaast investeren ook het Agentschap Ondernemen en de Provincie Oost-Vlaanderen in dit project. Met de fondsen worden grote bioreactoren en de bijbehorende randapparatuur aangekocht en geïnstalleerd in de proeffabriek in de Gentse haven. De financierende partners zorgen er zo voor dat Vlaanderen koploper blijft op vlak van industriële biotechnologie én een belangrijke bijdrage blijft leveren aan de Europese innovatie-agenda. Bovendien zal deze investering de economische ontwikkeling in de regio en daarbuiten stimuleren. read more

Agfa HealthCare and Qaelum sign agreement for Dose Monitoring Solution (*) to optimize radiation exposure information across modalities, departments and institutions

24.11.2014

Agfa HealthCare announces today that it has signed an agreement with Qaelum for a strategic alliance on a dose monitoring system, to support the dose management needs of hospitals and imaging networks. Primary focus will be on the EMEA region. Radiation exposure is an issue for every player in a patient’s treatment, from the patient, to the referring physician, to the radiology department, to regulatory bodies and to researchers. The Dose Monitoring Solution will enable organizations to manage, analyze and balance their radiation dose management. read more

Bone Therapeutics Appoints Dr Guy Heynen as Chief Clinical and Regulatory Officer

24.11.2014

BONE THERAPEUTICS, the regenerative therapy company addressing unmet medical needs in the fields of bone diseases and orthopaedics, today announces the appointment of Dr Guy Heynen as Chief Clinical and Regulatory Officer. Dr Heynen will support Bone Therapeutics as it progresses its strong pipeline of regenerative bone disease and orthopaedic therapies through clinical development towards commercialisation. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print